Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Monday, October 19, 2026

Back to today

From X

@aleabitoreddit 1 click

Serenity on X

Last major $SIVE disclosure was 100M CW DFB laser capacity Q4 2027. And a new foundry partner (that makes 2 including Win Semi). Expected $JBL revenue coming in H1 2027 (with lasers for Jabil's 1.6T LRO scaling up H2 2027). There's channel checks along the way like CIOE where Sivers was engaged with Chinese pluggable makers + laser ASPs being raised. 70mW/100mW ranges were the most tight to Chinese pluggable makers, which was surprising. Biggest industry read through was $LITE selling out into 2029, making agreements for 2030, and having hyperscalers pay for capacity expansion for 2031. I don't think anyone has enough information to do any sort of accurate modeling for $SIVE like you can for $AAOI given they don't release product breakdown + capacity targets by quarter. The 200mW NPO lasers Sivers is sampling is likely different ASP than your 70mW lasers shipped to pluggable makers. And your custom CPO lasers are different pricing too. Like all sampling/qualification players from $AEHR to $AAOI back in 2025, usually the risk/reward comes in whether qualifications convert and what new customers they have, which is always a risk. In a bull case, if $SIVE comes online with 300m laser supply (2:1 implied ratio, already has "tremendous" supply online from likely US fab) during a structural shortage. Pluggable players like $JBL, 6 other vendors. $GFS as the reference design laser for their CPO/NPO platform. Your minor players vendors like $POET, $AEVA and other players end up scaling. And all the other custom products they hinted they were working on in the past for CPO years back. I think the probability that they cook is higher since there's so many ongoing qualifications during a bottleneck. We've already seen ownership changes from Swedish investors to US/International retail from $SIVE shareholder disclosures. My guess is that trends institutional from retail before US listing next year amid the market correction. Think people forgot institutions have already financed their expansion, which was a 700M SEK round 100%+ ago (multiple times oversubscribed). And that $SIVE uses primarily external fabs, so it's not the same as a lot of the major financing concerns affecting Neoclouds. Anyway, up to management execution, I'm not running Sivers so no clue what other companies are working with them now, whether it's Cambridge or some other US player like Semtec. TLDR: - Just need to wait for earnings for more disclosures around qualifications + partners, only so much public can guess from channel checks and supplier mapping. Not quite the same as $LITE CEO where you can see the guy on Fox news or Bloomberg interviews every week (which is a good thing)
@aleabitoreddit 2 clicks

Serenity on X

Last time I've seen "It's all over" type posts was... 3 months ago during the situational awareness liquidation. And... 3 months ago before that... with Iran tensions + Oil + Helium + LNG fears/pricing. And... few months ago before that. I'm sure everyone remembers Deepseek back in like 2025 Each one had genuine risks, with rate hikes/margin liquidations to oil prices + supply disruption. And now financing/credit markets. Not trying to downplay the risks but haven't seen it materialize in the companies I'm tracking (eg. optical sector) given counterparty types + sector visibility + architectural shifts in 2027-2028. For example in this $LITE CEO interview, the guy said there hasn't been any order cancellation/delays given rate hikes. But obviously neocloud sector that uses heavy debt leverage might be different. I've seen that the general sentiment was a recovery after midterms in 2 weeks, I'm not the type to give predictions like that. We'll see Directionally bullish on certain sectors of AI supply chain like memory/photonics, but everything was sold off indiscriminately, even if they're not exactly the same trade.
@aleabitoreddit

Serenity on X

I can't give advice on what others should do but from what I'm seeing from $AAOI revenue ramp, it looks something like this from disclosed capacity. -> $858M Q1 2027 -> $1.29B Q2 2027 -> $1.62B Q3 2027 -> $1.89B Q4 2027 -> $2.14B Q1 2028 They're sitting on $6.8B MC right now. I'd be very impressed if they do $7.5B exit annualized revenue run rate in 2027 off 40% gross margins and markets assigned them the same valuation. And judging from $LITE making capacity agreements into 2030-2031... I don't quite think demand stalls out after 2027-2028. Anyway, lot of execution risk obviously, but H1 2027 inflection point is pretty close, so I'm personally waiting.
@aleabitoreddit 2 clicks

Serenity on X

$LITE CEO interview on demand, counterparty + financing risk: - "CFO of $GOOGL came on and reported capex going up Y/Y, we expect hyperscalers for report an increase in capex in earnings. Based on what we see, we see their spend going up." - "The purchase agreements we have, to a large degree, are noncancellable." - The difference between Lumentum and companies like $AVGO, "we are not as dependent on AI datacenter buildout going forward" There's a conversion between electrical products to optical products" creating structural demand. Q: When do you see able to see yourself having more inventory? (catching up to surge in demand) - When we look at demand, there is "no end in sight" TLDR: Financing risk and demand aren't equally distributed across AI supply chains. But markets are just selling everything off together. As for photonics in specific, I said this before, but increasing optical content per XPU + CPO/NPO adoption keeps going up so we'll likely see sector spend go up, even if aggregate capex goes down. There's the usual "no end to demand in sight" commentary, but $LITE does have capacity commitments into 2029 now... and are negotiating for 2030. (with new information that most of which are likely hyperscalers + non-cancellable) So doesn't quite sound like it's all over for the AI trade, especially photonics.
@calvinblissett 8 clicks

Calvin Blissett on X

$CCLD questions I have so far for Stephen Synder (CEO) interview if I am missing anything please let me know Charlie Munger famously talked about the importance of distinguishing between technological improvements where the economic benefits “stick to our ribs as owners” and those where “all of the advantages from great improvements are going to flow through to the customers.” (Stripe Press) I think it’s fair to say AI will lower costs overall for the RCM industry for those able to take advantage of it. McKinsey estimates that AI enablement of the revenue cycle could reduce cost to collect by 30% to 60%. (McKinsey & Company) We are already beginning to see this play out: roughly 20% to 40% of organizations report broad or enterprise-wide use of AI-enabled tools across different parts of the revenue cycle, while 70% to 90% of decision-makers expect to increase spending on AI-enabled RCM capabilities over the next three years. (Oliver Wyman) How is this playing out currently, and how do you see it progressing? More specifically, where do you think the economic benefits of AI ultimately accrue? Will AI make the strong stronger and the weak weaker—allowing scaled, technologically capable RCM providers to lower their costs faster and potentially furthering industry consolidation? Or, as AI tools become increasingly commoditized and accessible, could they instead level the playing field and erode some of CareCloud’s existing competitive cost advantage? A bit similar to the last question: Could AI change the dynamic of struggling companies not being able to upgrade products and or win clients. Allowing them to improve and compete hence lowering acquisition opportunities? How much growth aside from obviously inorganic acquisitions is existing customers expanding versus new clinics signing up? Do you think about size when acquiring or is it purely a factor of opportunity and fit. It would seem intuitive smaller acquisitions are easier and cheaper. Is there a pace or target you have in mind regarding acquisitions One shareholder asked for more metrics/metrics with news. Just granularity, Shareholder assumes it will be on earnings call but affects of data breach and portion if any that isn’t covered by insurance. What you’re seeing and anticipate seeing in terms of loss of current customers and momentum in future sales. A majority of the employees are in Pakistan which is currently going through a turbulent time and is basically a junta. Do you think there's any need to de-risk it? I believe the ROI from acquisition is at the midpoint of purchase multiple (.6-1x) and target contribution margin (25-30%) on a full year time frame after 9 months to get there to be About 34%. If your stock had the same FCF yield how would you weight buybacks vs acquisitions. Given the same assumed 34% full year after achieving targets on acquisition In Q2 2026, Hadi said: “OurAI and acquisition strategies have become a single, unified growth engine.” Does that mean that AI strategy/product development has similar economics or is it table stakes and has to be invested in merely to keep up?

Investor Letters

All letters

LXS.DE: a 2028 sale it can force

Lanxess can force Advent to buy at least half its Envalior stake in April 2028, potentially raising about €745 million to reduce net debt.

LPTH $525M
Trade Ideas Flow 14 clicks

Build-A-Bear: A Narrower Path

Build-A-Bear's push into prestuffed toys and broader retail distribution tests brand stretchability, but recent results warrant caution.

BBW $317M
TSOH Investment Research 13 clicks
SKIN · long

Skinhealth Systems INC

SkinHealth Systems owns a dominant professional skincare consumables franchise but trades at roughly $115 million market cap and $255…

SKIN $73M
Value Investors Club 1 click

Semtech Analyst Day Review

Semtech raised Q3 guidance and targets $3.2 billion of fiscal 2030 revenue, excluding upside from its AI data-center optical and copper…

SMTC $16B
CV's Substack 13 clicks

Publications we follow

Every publication on this site, hand-picked.

128 publications

Newsletters 107

YouTube 4

Blogs 16

Seeking Alpha 52 of 241

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

90 accounts
Nominate an account

Investor letters we follow

189 firms

Sectors

Ordered by how often our editor reaches for them.